about
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesPotential role of dipeptidyl peptidase IV in the pathophysiology of heart failureSystematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentUnderstanding and overcoming metformin gastrointestinal intolerance.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Diabetes medications: Impact on inflammation and wound healingFactor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.Non-alcoholic fatty liver disease and diabetes.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Inhibiting or antagonizing glucagon: making progress in diabetes care.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.Investigational insulin secretagogues for type 2 diabetes.Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Pharmacotherapy of 'treatment resistant' type 2 diabetes.Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pharmacological management of type 2 diabetes: what's new in 2017?Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Q26777177-634B21E3-87B8-44C7-8936-8CD5D59F79FAQ26829634-AC31C508-2F07-4428-9F40-1A308F64EAD7Q28075368-7D74398C-2239-4A58-AEDF-5A6BB869929EQ30240030-569CB5D4-325F-4016-AA40-8162E799BAB0Q35928257-37DEB615-FBB1-4B10-803D-DB90684A582EQ36132590-FF1287C7-C3AC-4AB6-A9E3-3DB0E3CE4BBEQ36429742-2F374719-029B-4273-914E-63EF2FD16781Q36805643-9A4801A2-E101-4D5D-83A1-BB7643367DBAQ36856980-C74B8193-843C-4ED6-98C2-ADECDC75CBC8Q37091659-DA4B041C-C08A-4549-B272-C10B8BB8E417Q37722896-46C335C3-B7DB-41ED-BD40-D3235DD89209Q38335751-C3F2FED3-EF9B-4C77-AAD8-7DD406604F1EQ38449296-0458A75F-EFB2-49B8-ADA1-106274AABB9DQ38455771-1A73D0EA-1D60-4474-ABCD-C93F52AAF94FQ38599145-64DFB7D7-4257-4D79-A231-51227472997FQ38735419-9AB623E0-D3EF-423E-B825-D714D826333DQ38813948-FAB4A84B-AAFE-4377-A31A-75C4785BF247Q38833312-267D57FE-699E-485E-B11F-D2BF482212BDQ38856808-16C433A3-332B-421B-A6AF-FC5C42728CF3Q38902321-E64BDB79-9623-445D-BA3A-69228CAC8956Q39063447-0064BC61-8050-4BB4-A534-517BED291DF0Q39170345-60B5E16D-3F2F-479F-B799-9565E8DA52C2Q40113914-0002F227-F36F-4BFF-BD5A-E1296A2C6198Q41090670-1B288E31-6141-45EC-875C-9DF39BB4A898Q42138923-6CF8100A-09C1-4656-955F-5BDF5D674962Q47687852-A5C24AD5-49E4-47C6-84B2-972735E2B25EQ47696671-961944F5-773A-4021-84A1-3404AB508D82Q48926149-6E0E8041-D298-4208-9EAD-318BD7E69FD8Q50348623-0609B3C4-87FB-4937-9856-EACB050F124DQ50679616-F5095988-6791-471A-9075-C1B41C77D352Q50997819-084349E1-30ED-4256-85BF-AA5FBFCE5497Q55053753-D403157B-6998-4D07-A762-D794F9B9B039
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A review of gliptins for 2014.
@en
type
label
A review of gliptins for 2014.
@en
prefLabel
A review of gliptins for 2014.
@en
P2860
P1476
A review of gliptins for 2014.
@en
P2093
André J Scheen
P2860
P356
10.1517/14656566.2015.978289
P407
P577
2014-11-10T00:00:00Z